Commonwealth Coat of Arms of Australia

National Health (Minimum Stockholding) Determination 2023

PB 65 of 2023

made under subsection 99AEKC(2) of the

National Health Act 1953

**Compilation No.** **6**

**Compilation date:** 1 March 2024

**Includes amendments:** F2024L00228

**Registered:** 15 March 2024

**About this compilation**

**This compilation**

This is a compilation of the *National Health (Minimum Stockholding) Determination 2023* that shows the text of the law as amended and in force on 1 March 2024 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

1 Name 1

3 Authority 1

4 Definitions 1

5 Usual PBS demand 1

Part 2—Minimum stockholding requirement 3

6 Applicable quantity of a brand of a pharmaceutical item 3

Schedule 1—Applicable quantity of a brand of a pharmaceutical item 4

Endnotes 34

Endnote 1—About the endnotes 34

Endnote 2—Abbreviation key 35

Endnote 3—Legislation history 36

Endnote 4—Amendment history 37

Part 1—Preliminary

1 Name

(1) This instrument is the *National Health (Minimum Stockholding) Determination 2023*.

(2) This instrument may also be cited as PB 65 of 2023.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Definitions

In this instrument:

***Act*** means the *National Health Act 1953*.

***brand*** has the same meaning as in Part VII of the Act.

***data collection period*** has the same meaning as in the *National Health (Pharmaceutical Benefits) Regulations 2017*.

***pharmaceutical benefit*** has the same meaning as in Part VII of the Act.

***pharmaceutical item*** has the same meaning as in Part VII of the Act.

***pricing quantity*** has the same meaning as in Part VII of the Act.

***usual demand***, when used in relation to a brand of a pharmaceutical item, means the usual demand for the brand of the pharmaceutical item within the meaning of section 99AEKC of the Act.

***usual PBS*** ***demand***, when used in relation to a brand of a pharmaceutical item, means the usual PBS demand for the brand of the pharmaceutical item ascertained in accordance with section 5.

5 Usual PBS demand

(1) The usual PBS demand for a brand of a pharmaceutical item for a month in a data collection period for that brand is the number of packs of the brand supplied during the data collection period (***the reference period***) before the previous data collection period for the brand divided by the number of months in the reference period.

(2) For the purposes of subsection (1) the number of packs of the brand supplied during a data collection period is taken to be:

(a) the number of packs of the brand supplied as pharmaceutical benefits during that period; and

(b) adjusted as if the size of the pack equals the pricing quantity of the brand.

(3) For the purposes of this section, a brand of pharmaceutical item to which section 99ADHC and therefore 99AEKA of the Act applies, but to which section 99ADD of the Act does not apply, is treated as if data collection periods applied to the brand, and as if the start day for the first data collection period for the brand was the day on which that brand was first determined under subsection 85(6) of the Act.

Part 2—Minimum stockholding requirement

6 Applicable quantity of a brand of a pharmaceutical item

For the purposes of subparagraphs 99AEKC(1)(a)(ii) and (1)(b)(ii) of the Act, if a brand of a pharmaceutical item is specified in an item of column 4 of the table in Schedule 1 to this instrument, the quantity ascertained in accordance with column 5 of that item is the applicable quantity of the brand of the pharmaceutical item.

Schedule 1—Applicable quantity of a brand of a pharmaceutical item

Note: See section 6.

| Applicable quantity of a brand of a pharmaceutical item | | | | |
| --- | --- | --- | --- | --- |
| Column 1 Drug | Column 2 Form | Column 3 Manner of administration | **Column 4 Brand** | Column 5 Applicable quantity |
| Acarbose | Tablet 100 mg | Oral | Acarbose Viatris | 4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together |
| Acarbose | Tablet 100 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Allosig | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Zyloprim | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | Zyloprim | 4 months stock by reference to usual demand |
| Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral | PKU squeezie | 0 months stock by reference to usual PBS demand |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APX‑Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand  (b) after 31 December 2023—5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APX‑Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand  (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand  (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Amlodipine | Tablet 10 mg (as besilate) | Oral | Norvapine | between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Amlodipine | Tablet 5 mg (as besilate) | Oral | Norvapine | between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |
| Amphotericin B | Lozenge 10 mg | Oral | Fungilin | 4 months stock by reference to usual PBS demand |
| Aripiprazole | Tablet 10 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 10 mg | Oral | Aripic Aripiprazole | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral | Atenolol‑AFT | 4 months stock by reference to usual PBS demand |
| Atenolol | Tablet 50 mg | Oral | APX‑Atenolol | 4 months stock by reference to usual demand |
| Atenolol | Tablet 50 mg | Oral | Tensig | 4 months stock by reference to usual demand |
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 100 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 18 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 25 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 40 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 60 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atorvastatin | Tablet 10 mg (as calcium) | Oral | Atorvastatin GH | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Atorvastatin | Tablet 40 mg (as calcium) | Oral | Atorvastatin GH | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral | Zithromax | 4 months stock by reference to usual PBS demand |
| Baclofen | Tablet 10 mg | Oral | APO‑Baclofen | 3 months stock by reference to usual demand |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | 3 months stock by reference to usual demand |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan Cipla | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Capecitabine | Tablet 150 mg | Oral | Capecitabine-DRLA | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the Eye | Refresh Liquigel | 4 months stock by reference to usual PBS demand |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the Eye | Refresh Tears Plus | 4 months stock by reference to usual PBS demand |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | 4 months stock by reference to usual PBS demand |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the Eye | Chlorsig | 4 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral | Largactil | 4 months stock by reference to usual PBS demand |
| Chlortalidone | Tablet 25 mg | Oral | Hygroton 25 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 10 mg | Oral | Neoral 10 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 100 mg | Oral | APO‑Ciclosporin | 2.5 months stock by reference to usual demand |
| Ciclosporin | Capsule 25 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Capsule 50 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharma Pty Ltd | 4 months stock by reference to usual PBS demand |
| Dantrolene | Capsule containing dantrolene sodium hemiheptahydrate 25 mg | Oral | Dantrium | 6 months stock by reference to usual PBS demand |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | Diclofenac Sandoz | between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | Fenac 25 | between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Diclofenac Sandoz | between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Fenac | between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral | Diltiazem AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Domperidone | Tablet 10 mg | Oral | Motilium | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together |
| Dosulepin | Tablet containing dosulepin hydrochloride 75 mg | Oral | Dosulepin Viatris 75 | 6 months stock by reference to usual demand of both Dosulepin Viatris 75 and Dosulepin Mylan added together |
| Doxorubicin ‑ pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxorubicin ‑ pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX‑Doxycycline | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Enalapril generichealth | between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | APO‑Enalapril | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | Malean | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Acetec | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—2 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Enalapril generichealth | between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral | Lexapro | 4 months stock by reference to usual PBS demand |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | APO‑Ezetimibe/Simvastatin 10/10 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | APO‑Ezetimibe/Simvastatin 10/20 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | APO‑Ezetimibe/Simvastatin 10/40 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | APO‑Ezetimibe/Simvastatin 10/80 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Felodur ER 2.5 mg | 2.5 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
| Fenofibrate | Tablet 145 mg | Oral | Fenofibrate Viatris | 6 months stock by reference to usual demand of both Fenofibrate Viatris and Fenofibrate Mylan added together |
| Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 12.6 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 16.8 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO‑Fentanyl | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand  (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 4.2 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the Eye | FML Liquifilm | 2 months stock by reference to usual PBS demand |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand |
| Folic acid | Tablet 5 mg | Oral | Megafol 5 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Foltabs 500 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 | 4 months stock by reference to usual PBS demand |
| Folinic acid | Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL | Injection | Leucovorin Calcium (Pfizer Australia Pty Ltd) | between 1 March 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Fosinopril | Tablet containing fosinopril sodium 10 mg | Oral | APO‑Fosinopril | 3 months stock by reference to usual demand |
| Fosinopril | Tablet containing fosinopril sodium 20 mg | Oral | APO‑Fosinopril | 3 months stock by reference to usual demand |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL | Application to the Eye/Ear | Soframycin | 4 months stock by reference to usual PBS demand |
| Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 4 months stock by reference to usual PBS demand |
| Gabapentin | Capsule 400 mg | Oral | GAPENTIN | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 16 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 24 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Galantyl | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—1.5 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Glimepiride | Tablet 1 mg | Oral | Aylide 1 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Glimepiride | Tablet 2 mg | Oral | Aylide 2 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Glimepiride | Tablet 3 mg | Oral | Aylide 3 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Glimepiride | Tablet 4 mg | Oral | Aylide 4 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Glucose and ketone indicator‑urine | Test strips, 50 (Keto‑Diastix) | For External Use | Keto‑Diastix | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 1.5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 500 micrograms | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Heparin | Injection 5,000 units (as sodium) in 0.2 ml | Injection | DBL Heparin Sodium | 6 months stock by reference to usual PBS demand |
| Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral | Alphapress 25 | between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand |
| Hydrocortisone | Tablet 20 mg | Oral | Hydrocortisone Viatris 20 | 4 months stock by reference to usual demand of both Hydrocortisone Viatris 20 and Hydrocortisone Mylan 20 added together |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | Genteal | 4 months stock by reference to usual demand |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | 4 months stock by reference to usual demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand |
| Indapamide | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Insig | 3 months stock by reference to usual demand |
| Insect allergen extract‑honey bee venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Honey Bee Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insect allergen extract‑paper wasp venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Paper Wasp Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Lamivudine with zidovudine | Tablet 150 mg-300 mg | Oral | Lamivudine/Zidovudine Viatris 150/300 | after 31 May 2024—4 months stock by reference to usual demand of both Lamivudine/Zidovudine Viatris 150/300 and Lamivudine 150 mg + Zidovudine 300 mg Alphapharm added together |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand  (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | 3 months stock by reference to usual demand |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost | 2 months stock by reference to usual demand |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost/Timolol 0.05/5 | 2.5 months stock by reference to usual demand |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Macrogol 3350 | Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL | Oral | Movicol Liquid | between 1 January 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Macrogol 3350 | Powder for oral solution 510 g | Oral | OsmoLax | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox | 6 months stock by reference to usual PBS demand |
| Methylprednisolone | Powder for injection 40 mg (as sodium succinate) | Injection | Methylpred | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | Metrol 100 | 4 months stock by reference to usual demand |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | Metrol 50 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Modafinil | Tablet 100 mg | Oral | Modafin | 3 months stock by reference to usual demand |
| Morphine | Tablet containing morphine sulfate pentahydrate 30 mg | Oral | Anamorph | 3 months stock by reference to usual demand |
| Moxonidine | Tablet 200 micrograms | Oral | Moxonidine Viatris | 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together |
| Moxonidine | Tablet 400 micrograms | Oral | Moxonidine Viatris | 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together |
| Mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | Oral | CellCept | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | CellCept | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Nevirapine | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral | Viramune | 4 months stock by reference to usual PBS demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | APO‑Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | APO‑Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—2 months stock by reference to usual demand |
| Norfloxacin | Tablet 400 mg | Oral | APO‑Norfloxacin | 2.5 months stock by reference to usual demand |
| Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral;  (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand  (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;  (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together. |
| Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;  (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | 3 months stock by reference to usual demand |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;  (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | OLMERTAN | 3 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand  (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 20/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 40/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | OLMERTAN COMBI 40/25 | 3 months stock by reference to usual demand |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
| Oxazepam | Tablet 30 mg | Oral | APO‑Oxazepam | 5.5 months stock by reference to usual demand |
| Oxazepam | Tablet 30 mg | Oral | Murelax | 5 months stock by reference to usual demand |
| Oxybutynin | Tablet containing oxybutynin hydrochloride 5 mg | Oral | Ditropan | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |
| Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL | Oral | OxyNorm Liquid 1mg/mL | 4 months stock by reference to usual PBS demand |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | 4 months stock by reference to usual PBS demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO‑Pantoprazole | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Paraffin with retinol palmitate | Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g | Application to the Eye | VitA-POS | between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 4 months stock by reference to usual PBS demand |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand  (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Indosyl Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand  (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand  (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg‑3 mg per mL, 15 mL | Application to the Eye | Systane | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |
| Pregabalin | Capsule 150 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pregabalin | Capsule 25 mg | Oral | Cipla Pregabalin | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 25 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |
| Pregabalin | Capsule 300 mg | Oral | Cipla Pregabalin | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 300 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |
| Pregabalin | Capsule 75 mg | Oral | Cipla Pregabalin | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 75 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Probenecid | Tablet 500 mg | Oral | Pro‑Cid | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | Stemzine | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Quinapril | Tablet 10 mg (as hydrochloride) | Oral | APO‑Quinapril | 3 months stock by reference to usual demand |
| Quinapril | Tablet 20 mg (as hydrochloride) | Oral | APO‑Quinapril | 3 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO‑Rabeprazole | 4 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | 4 months stock by reference to usual demand |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | RALOVISTA | 3 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | APX‑Ramipril | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | Prilace | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Prilace | 2.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Tryzan Tabs 1.25 | (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand  (b) after 31 December 2023—3 months stock by reference to usual demand |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | 4 months stock by reference to usual PBS demand |
| Risedronic acid | Tablet containing risedronate sodium 150 mg | Oral | APO‑Risedronate | 3 months stock by reference to usual demand |
| Risperidone | Tablet 1 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |
| Risperidone | Tablet 2 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | APO‑Risperidone | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand  (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |
| Risperidone | Tablet 4 mg | Oral | Risperidone generichealth | between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Roxithromycin | Tablet 150 mg | Oral | APX‑Roxithromycin | 4 months stock by reference to usual demand |
| Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand  (b) after 31 December 2023—5 months stock by reference to usual demand |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | Inhalation by Mouth | Asmol CFC‑Free with dose counter | between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | Inhalation by Mouth | Zempreon CFC‑Free with dose counter | between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Enemas 3.125 g‑450 mg‑45 mg in 5 mL, 12 | Rectal | Micolette | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—1.5 months stock by reference to usual demand |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | APO‑Sumatriptan | 4 months stock by reference to usual demand |
| Tacrolimus | Capsule 1 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Temazepam | Tablet 10 mg | Oral | APO‑Temazepam | 2.5 months stock by reference to usual demand |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Tenofovir Disoproxil Emtricitabine Viatris 300/200 | after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit | 4 months stock by reference to usual PBS demand |
| Tobramycin | Injection 80 mg in 2 mL | Injection | Tobramycin Viatris | 4 months stock by reference to usual demand of both Tobramycin Viatris and Tobramycin Mylan added together |
| Topiramate | Tablet 100 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 100 mg | Oral | Topamax | between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Topiramate | Tablet 200 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 200 mg | Oral | Topamax | between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Topiramate | Tablet 25 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 25 mg | Oral | Topamax | between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Topiramate | Tablet 50 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 50 mg | Oral | Topamax | between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand |
| Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL | Oral | Tramal | 4 months stock by reference to usual PBS demand |
| Trandolapril | Capsule 1 mg | Oral | Dolapril 1 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 2 mg | Oral | Dolapril 2 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 4 mg | Oral | Dolapril 4 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 500 micrograms | Oral | Dolapril 0.5 | 2.5 months stock by reference to usual demand |
| Triglycerides—medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | 0 months stock by reference to usual PBS demand |
| Triglycerides, medium chain | Oral liquid 225 mL, 15 (K.Quik) | Oral | K.Quik | 0 months stock by reference to usual PBS demand |
| Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together |
| Tropisetron | I.V. injection 5 mg (as hydrochloride) in 5 mL | Injection | Tropisetron-AFT | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | 4 months stock by reference to usual PBS demand |
| Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | Valganciclovir Viatris | 4 months stock by reference to usual demand of both Valganciclovir Viatris and Valganciclovir Mylan added together |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Liquid | 4 months stock by reference to usual PBS demand |
| Valproic acid | Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Syrup | 4 months stock by reference to usual PBS demand |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | 4 months stock by reference to usual PBS demand |
| Vinorelbine | Solution for I.V. infusion 10 mg (as tartrate) in 1 mL | Injection | Navelbine | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |
| Voriconazole | Tablet 200 mg | Oral | Vfend | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| National Health (Minimum Stockholding) Determination 2023 (PB 65 of 2023) | 30 June 2023 (F2023L00919) | 1 July 2023 (s 2(1) item 1) |  |
| National Health (Minimum Stockholding) Amendment Determination (No. 1) 2023 (PB 103 of 2023) | 29 Sept 2023 (F2023L01338) | 1 Oct 2023 (s 2(1) item 1) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023 (PB 111 of 2023) | 31 Oct 2023 (F2023L01455) | 1 Nov 2023 (s 2(1) item 1) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023 (PB 125 of 2023) | 30 Nov 2023 (F2023L01573) | 1 Dec 2023 (s 2(1) item 1) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023 (PB 136 of 2023) | 18 Dec 2023 (F2023L01702) | Sch 2: 1 Feb 2024 (s 2(1) item 3) Sch 3: 1 Apr 2024 (s 2(1) item 4) Remainder: 1 Jan 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024 (PB 10 of 2024) | 31 Jan 2024 (F2024L00114) | Sch 2: 1 June 2024 (s 2(1) item 3) Remainder: 1 Feb 2024 (s 2(1) items 1, 2) | — |
| National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024 (PB 24 of 2024) | 29 Feb 2024 (F2024L00228) | 1 Mar 2024 (s 2(1) items 1, 2) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Part 1** |  |
| s 2 | rep LA s 48D |
| s 5 | am F2023L01338 |
| **Schedule 1** |  |
| Schedule 1 | am F2023L01338 |
|  | rs F2023L01455 |
|  | am F2023L01455; F2023L01573 |
|  | ed C3 |
|  | am F2023L01702 (Sch 3); F2024L00114 (Sch 2) |
|  | ed C5 |
|  | am F2024L00228 |